229 related articles for article (PubMed ID: 17922676)
1. DMOAD developments: present and future.
Pelletier JP; Martel-Pelletier J
Bull NYU Hosp Jt Dis; 2007; 65(3):242-8. PubMed ID: 17922676
[TBL] [Abstract][Full Text] [Related]
2. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?
Qvist P; Bay-Jensen AC; Christiansen C; Dam EB; Pastoureau P; Karsdal MA
Pharmacol Res; 2008 Jul; 58(1):1-7. PubMed ID: 18590824
[TBL] [Abstract][Full Text] [Related]
3. Osteoarthritis in 2007.
Krasnokutsky S; Samuels J; Abramson SB
Bull NYU Hosp Jt Dis; 2007; 65(3):222-8. PubMed ID: 17922674
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis.
Abadie E; Ethgen D; Avouac B; Bouvenot G; Branco J; Bruyere O; Calvo G; Devogelaer JP; Dreiser RL; Herrero-Beaumont G; Kahan A; Kreutz G; Laslop A; Lemmel EM; Nuki G; Van De Putte L; Vanhaelst L; Reginster JY;
Osteoarthritis Cartilage; 2004 Apr; 12(4):263-8. PubMed ID: 15023377
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacy clinics. How I treat...Osteoarthritis. 2nd part: new therapeutic perspectives].
Reginster JY; Henrotin Y
Rev Med Liege; 2001 Mar; 56(3):135-9. PubMed ID: 11338782
[TBL] [Abstract][Full Text] [Related]
6. [Review of the evidence about drugs used as SYSADOA].
Sanfélix-Gimeno G; Reig-Mollá B; Sanfélix-Genovés J; Giner-Ruiz V
Med Clin (Barc); 2007 Nov; 129(16):624-8. PubMed ID: 18001676
[No Abstract] [Full Text] [Related]
7. Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis.
Pelletier JP
Osteoarthritis Cartilage; 2004; 12 Suppl A():S63-8. PubMed ID: 14698646
[TBL] [Abstract][Full Text] [Related]
8. [Role of slow-acting anti-arthritic agents in osteoarthritis (chondroitin sulfate, glucosamine, hyaluronic acid)].
Aubry-Rozier B
Rev Med Suisse; 2012 Mar; 8(332):571-2, 574, 576. PubMed ID: 22455150
[TBL] [Abstract][Full Text] [Related]
9. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs.
Verbruggen G; Goemaere S; Veys EM
Clin Rheumatol; 2002 Jun; 21(3):231-43. PubMed ID: 12111630
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic therapy for osteoarthritis--the era of disease modification.
Hunter DJ
Nat Rev Rheumatol; 2011 Jan; 7(1):13-22. PubMed ID: 21079644
[TBL] [Abstract][Full Text] [Related]
11. Future treatment of osteoarthritis.
Baker CL; Ferguson CM
Orthopedics; 2005 Feb; 28(2 Suppl):s227-34. PubMed ID: 15747611
[TBL] [Abstract][Full Text] [Related]
12. Use of glucosamine and chondroitin in persons with osteoarthritis.
Sherman AL; Ojeda-Correal G; Mena J
PM R; 2012 May; 4(5 Suppl):S110-6. PubMed ID: 22632689
[TBL] [Abstract][Full Text] [Related]
13. Glucosamine/chondroitin/primorine combination therapy for osteoarthritis.
Fox BA; Stephens MM
Drugs Today (Barc); 2009 Jan; 45(1):21-31. PubMed ID: 19271029
[TBL] [Abstract][Full Text] [Related]
14. Arthritis clinical trial results revealed.
Hampton T
JAMA; 2007 Jan; 297(1):28-9. PubMed ID: 17200465
[No Abstract] [Full Text] [Related]
15. OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials.
Manno RL; Bingham CO; Paternotte S; Gossec L; Halhol H; Giacovelli G; Rovati L; Mazzuca SA; Clegg DO; Shi H; Tajana Messi E; Lanzarotti A; Dougados M
Osteoarthritis Cartilage; 2012 Feb; 20(2):93-101. PubMed ID: 22178465
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of drugs used in degenerative joint diseases (arthroses)].
Sanfélix-Gimeno G; Reig-Mollá B; Sanfélix-Genovés J; Giner-Ruiz V
Med Clin (Barc); 2008 Apr; 130(12):463-5. PubMed ID: 18405503
[No Abstract] [Full Text] [Related]
17. Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents.
Gallagher B; Tjoumakaris FP; Harwood MI; Good RP; Ciccotti MG; Freedman KB
Am J Sports Med; 2015 Mar; 43(3):734-44. PubMed ID: 24866892
[TBL] [Abstract][Full Text] [Related]
18. Chondroitin Sulfate and Glucosamine as Disease Modifying Anti- Osteoarthritis Dru gs (DMOADs).
Mantovani V; Maccari F; Volpi N
Curr Med Chem; 2016; 23(11):1139-51. PubMed ID: 26980567
[TBL] [Abstract][Full Text] [Related]
19. Intra-articular human deciduous dental pulp stem cell administration vs. pharmacological therapy in experimental osteoarthritis rat model.
Correa Maldonado D; Nicoliche T; Faber J; Kerkis I; Martinez Saez D; Tetsuo Sasaki R; Cavenaghi Pereira da Silva M
Eur Rev Med Pharmacol Sci; 2021 May; 25(9):3546-3556. PubMed ID: 34002829
[TBL] [Abstract][Full Text] [Related]
20. Prospects of Disease-Modifying Osteoarthritis Drugs.
Oo WM
Rheum Dis Clin North Am; 2024 Aug; 50(3):483-518. PubMed ID: 38942581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
